FDA
-
-
-
-
-
-
-
Adicet Bio Announces Reverse Stock Split
-
-
-
-
-
-
-
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Adicet Bio Inc. (ACET)
-
-
-
-
-
-
-
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
-
-
-
-
-
-
-
Adicet Bio (ACET) Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
-
-
-
-
-
-
-
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
-
-
-
-
-
-
-
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

